Alnylam Pharmaceuticals, Inc. $ALNY Stock: Illinois Municipal Retirement Fund Reduces Stake

Illinois Municipal Retirement Fund decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 33.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,221 shares of the biopharmaceutical company’s stock after selling 8,054 shares during the period. Illinois Municipal Retirement Fund’s holdings in Alnylam Pharmaceuticals were worth $4,002,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of ALNY. Toth Financial Advisory Corp acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $25,000. Burkett Financial Services LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $37,000. CoreCap Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 744.4% during the 3rd quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 134 shares during the last quarter. Keating Financial Advisory Services Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $42,000. Finally, Root Financial Partners LLC bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $48,000. 92.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on ALNY. Citigroup lowered their target price on Alnylam Pharmaceuticals from $340.00 to $320.00 and set a “buy” rating on the stock in a report on Wednesday, October 14th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 30th. BMO Capital Markets reiterated an “outperform” rating and set a $290.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, October 30th. Raymond James Financial cut Alnylam Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and reduced their price objective for the company from $420.00 to $315.00 in a research report on Friday, October 30th. Finally, Canaccord Genuity Group reduced their price objective on Alnylam Pharmaceuticals from $429.00 to $323.00 and set a “buy” rating for the company in a research report on Monday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $305.86.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY traded up $8.39 during trading hours on Friday, reaching $165.04. 3,589,267 shares of the company traded hands, compared to its average volume of 3,176,010. The stock’s fifty day moving average is $219.25 and its 200 day moving average is $276.00. The stock has a market cap of $22.11 billion, a P/E ratio of 8.57 and a beta of 0.42. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.43 and a current ratio of 2.48. Alnylam Pharmaceuticals, Inc. has a 1-year low of $149.18 and a 1-year high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, beating the consensus estimate of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter last year, the company earned $2.90 earnings per share. The firm’s revenue was up 16.7% on a year-over-year basis. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the transaction, the executive vice president owned 12,807 shares of the company’s stock, valued at $2,905,652.16. This represents a 12.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.